Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure-Reference-Cited by-同舟云学术

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

Published:2024-03 Issue:3 Volume:6 Page:100994
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Graf Christiana,D’Ambrosio Roberta,Degasperi Elisabetta^ORCID,Paolucci Stefania,Llaneras Jordi,Vermehren Johannes,Dultz Georg,Peiffer Kai-Henrik,Finkelmeier Fabian^ORCID,Herrmann Eva,Zeuzem Stefan,Buti Maria,Lampertico Pietro^ORCID,Dietz Julia,Sarrazin Christoph

Funder

Deutsches Zentrum für Infektionsforschung

Publisher

Elsevier BV

Reference46 articles.

1. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs;Naggie;Annu Rev Med,2017

2. Tu1033 evaluation of access to care in patients prescribed sofosbuvir-containing regimens: data from the TRIO network;Younossi;Gastroenterology,2015

3. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor;Lawitz;Antivir Ther,2018

4. EASL recommendations on treatment of hepatitis C 2018;J Hepatol,2018

5. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;Hepatol Baltim Md,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients;JHEP Reports;2024-07

2. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis;Swiss Medical Weekly;2024-06-24

3. Editorial: Retreatment of direct‐acting antiviral failures with the current first‐line regimens for patients with chronic hepatitis C;Alimentary Pharmacology & Therapeutics;2024-06-16

4. Early treatment of acute or recently acquired hepatitis C: An important tool on the path to HCV elimination!;Hepatology;2024-06-05

5. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir;Alimentary Pharmacology & Therapeutics;2024-05-02